Gladstone Capital Management LLP Decreases Stock Holdings in The Cooper Companies, Inc. (NASDAQ:COO)

Gladstone Capital Management LLP trimmed its holdings in shares of The Cooper Companies, Inc. (NASDAQ:COO - Free Report) by 99.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,000 shares of the medical device company's stock after selling 760,080 shares during the quarter. Cooper Companies accounts for about 0.0% of Gladstone Capital Management LLP's holdings, making the stock its 25th largest position. Gladstone Capital Management LLP's holdings in Cooper Companies were worth $92,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the business. Byrne Asset Management LLC purchased a new stake in Cooper Companies during the fourth quarter worth about $33,000. OFI Invest Asset Management purchased a new stake in shares of Cooper Companies during the 4th quarter worth approximately $34,000. New Age Alpha Advisors LLC purchased a new position in Cooper Companies in the fourth quarter valued at approximately $38,000. West Financial Advisors LLC purchased a new position in Cooper Companies in the fourth quarter valued at approximately $49,000. Finally, Atala Financial Inc bought a new position in Cooper Companies during the fourth quarter valued at $51,000. 24.39% of the stock is currently owned by institutional investors.

Cooper Companies Price Performance

Shares of NASDAQ COO traded down $3.80 during mid-day trading on Thursday, reaching $74.10. 959,423 shares of the company were exchanged, compared to its average volume of 1,875,778. The stock has a market capitalization of $14.82 billion, a PE ratio of 38.02, a PEG ratio of 2.25 and a beta of 1.01. The company has a quick ratio of 1.12, a current ratio of 1.91 and a debt-to-equity ratio of 0.32. The Cooper Companies, Inc. has a 52 week low of $69.81 and a 52 week high of $112.38. The company's 50 day moving average price is $85.39 and its 200 day moving average price is $95.08.

Remove Ads

Cooper Companies (NASDAQ:COO - Get Free Report) last issued its quarterly earnings results on Thursday, March 6th. The medical device company reported $0.92 EPS for the quarter, meeting analysts' consensus estimates of $0.92. The business had revenue of $964.70 million for the quarter, compared to analysts' expectations of $981.25 million. Cooper Companies had a net margin of 10.07% and a return on equity of 9.38%. Sell-side analysts forecast that The Cooper Companies, Inc. will post 3.98 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

COO has been the subject of several research reports. StockNews.com downgraded Cooper Companies from a "buy" rating to a "hold" rating in a research note on Wednesday, December 11th. Stifel Nicolaus cut their target price on shares of Cooper Companies from $115.00 to $105.00 and set a "buy" rating for the company in a research report on Friday, March 7th. Robert W. Baird dropped their target price on Cooper Companies from $117.00 to $107.00 and set an "outperform" rating on the stock in a research report on Friday, March 7th. JPMorgan Chase & Co. decreased their price target on Cooper Companies from $120.00 to $110.00 and set an "overweight" rating on the stock in a research report on Friday, March 7th. Finally, BNP Paribas upgraded shares of Cooper Companies to a "hold" rating in a research report on Thursday, March 13th. Four equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to data from MarketBeat, Cooper Companies currently has a consensus rating of "Moderate Buy" and an average target price of $110.25.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.